|
|
 |
|
Viewing report
|
|
|
|
The Diabetes Market Outlook: Market Analysis of Future Growth and Leading Players by Sector
Business Insights, Jan 2005
Chapter 1 Epidemiology analysis
Summary
Introduction
Disease description
Type 1 diabetes
Type 2 diabetes
Current and future prevalence of diabetes
Diagnosis
Fast-track review for diabetes drugs
Current and future treatment patterns
Insulin prescribing
TZD prescribing
Chapter 2 Global diabetes market analysis
Summary
Introduction
History of antidiabetic drugs
Current growth drivers
Insulins
TZDs
Combination therapies
Future growth drivers
Non-injected insulin
Inhaled insulins
Oral insulins
Insulin patches
Dual PPAR agonists
GLP-1 agonists and DPP IV inhibitors
GLP-1 agonists
DPP IV inhibitors
Amylinomimetic agents
Chapter 3 Insulin market analysis
Summary
Introduction
Insulin categories and sales
Company market share
Brand market share and sales
Human Insulins
Brand analysis
Humulin (human insulin)
NovoLin (human insulin)
Fast-acting human insulin analogs
Brand analysis
Humalog (insulin lispro)
NovoLog (insulin aspart)
Apidra (insulin glulisine)
Long-acting insulin analogs
Brand analysis
Lantus (insulin glargine)
Levemir (insulin detemir)
Chapter 4 Oral antidiabetic (OAD) market analysis
Summary
Introduction
OAD categories and sales
Company market share
Sulfonylurea products
Brand market share and sales
Brand analysis
Amaryl (glimepriride)
Glucotrol XL (glipizide)
Biguanide products
Brand market share and sales
Brand analysis
Glucophage & Glucophage XR (metformin)
Combined sulfonylurea & biguanide products (and other combination therapies)
Sulfonylurea + biguanide single-pill combination drugs
Glucovance (glyburide + metformin)
TZD + other OAD single-pill combination therapies
Thiazolidinedione (TZD) products
Brand market share and sales
Brand analysis
Drug analysis
Actos (pioglitazone)
Avandia (rosiglitazone)
Avandamet (rosiglitazone + metformin)
Alpha glucosidase inhibitor (AGI) products
Brand market share and sales
Brand analysis
Precose/Glucobay (acarbose)
Basen (voglibose)
Glyset/Diastabol (miglitol)
Other OAD products (the prandial glucose regulators)
Brand market shares and sales
Brand analysis
Prandin/NovoNorm (repaglinide)
Starlix (nateglinide)
Chapter 5 Leading players in the diabetes market
Summary
Introduction
Eli Lilly
Therapeutic focus
Insulin market share
Marketed products
R&D pipeline
Exenatide (synthetic exendin-4)
Ruboxistaurin
Pulmonary insulin (AIR)
Oralin
LY-818 (naveglitazar)
Novo Nordisk
Therapeutic focus
Insulin market share
Marketed products
R&D pipeline
NovoMix 50 and 70 (NN1185): Injectable insulin formulations
AERx iDMS (NN1998): An inhaled insulin
Liraglutide (NN2211)
Sanofi-Aventis
Therapeutic focus
Insulin and OAD market shares
R&D pipeline
Exubera
DiaPep
Takeda
Therapeutic focus
OAD market share
Marketed products
R&D pipeline
Actos/metformin combination
ATL-962
TAK-559
TAK-654
TAK-428
GlaxoSmithKline
Therapeutic focus
OAD market share
Marketed products
R&D pipeline
Avandaryl
Avandamet XR
HIM-2
677954
Bristol-Myers Squibb
Therapeutic focus
OAD market share
Marketed products
R&D pipeline
Muraglitazar
Basulin
Inhaled Insulin
Pfizer
Therapeutic focus
Marketed products
R&D pipeline
Exubera
Novartis
Therapeutic focus
Marketed products
R&D pipeline
LAF237
Merck KGaA
Therapeutic focus
Marketed products
R&D pipeline
Index
List of Figures
Figure 1.1: Prevalence of obese and overweight adults in US, 1976-2000
Figure 1.2: Proportion of type 2 diabetics diagnosed, 2003
Figure 1.3: Management of type 2 diabetes by physician type, 2003
Figure 1.4: Proportion of drug treated type 2 diabetics treated with insulin in monotherapy or combination, 2003
Figure 2.5: Development timeline for antidiabetic drug classes, 1920-2004
Figure 2.6: Overview of diagnosis rates, treatment rates and insulin prescribing trends in six major markets, 2003
Figure 2.7: Approved combination therapies for type 2 diabetes, 2003
Figure 2.8: Positive and negative developments influencing the antidiabetics market, 2004 & forwards
Figure 2.9: Overview of the non-invasive insulin pipeline, 2004
Figure 3.10: Insulin brands by company and type, 2004
Figure 3.11: US/European* market share of leading insulins (%), 1999-2003
Figure 3.12: Humulin SWOT analysis
Figure 3.13: NovoLin SWOT analysis
Figure 3.14: Humalog SWOT analysis
Figure 3.15: NovoLog SWOT analysis
Figure 3.16: Apidra SWOT analysis
Figure 3.17: Lantus SWOT analysis
Figure 3.18: Levemir SWOT analysis
Figure 4.19: Sales of OAD categories in Europe* and US ($m), 2003
Figure 4.20: Global* market share of leading sulfonylureas (%), 1999-2003
Figure 4.21: Amaryl SWOT analysis
Figure 4.22: Glucotrol XL SWOT analysis
Figure 4.23: Global* market share of leading biguanides, 1999-2003
Figure 4.24: Glucophage XR SWOT analysis
Figure 4.25: Glucovance SWOT analysis
Figure 4.26: US/European* market share of leading TZDs (%), 1999-2003
Figure 4.27: Actos SWOT analysis
Figure 4.28: Avandia SWOT analysis
Figure 4.29: Avandamet SWOT analysis
Figure 4.30: US/European* market share of leading AGIs (%), 1999-2003
Figure 4.31: Precose/Glucobay SWOT analysis
Figure 4.32: Basen SWOT analysis
Figure 4.33: US/European* market share of leading PGRs (%), 1999-2003
Figure 4.34: Prandin/NovoNorm SWOT analysis
Figure 4.35: Starlix SWOT analysis
Figure 5.36: Eli Lilly’s therapeutic focus, 2003-2010
Figure 5.37: Novo Nordisk’s therapeutic focus, 2003 and 2010
Figure 5.38: Sanofi-Aventis’ therapeutic focus, 2003 & 2010
Figure 5.39: Takeda’s therapeutic focus, 2003 & 2010
Figure 5.40: GSK’s therapeutic focus, 2003 & 2010
Figure 5.41: BMS’s changing therapeutic focus, 2003-2010
Figure 5.42: Pfizer’s changing therapeutic focus, 2003-10 1
Figure 5.43: Merck KGaA’s changing therapeutic focus, 2003 & 2010
List of Tables
Table 1.1: Prevalence of Type 2 diabetes (m), 2003-2012
Table 1.2: US and European* Sales by Drug Class ($m), 2002-2003
Table 2.3: US/European* sales category totals ($m), 2002-2003
Table 3.4: US/European* Sales of insulins by category ($m), 2002-2003
Table 3.5: Insulin market share by company and territory (%), 2002-2003
Table 3.6: Sales of leading insulins by country ($m), 2002-2003
Table 3.7: Branded human insulins
Table 3.8: Branded fast-acting human insulin analogs
Table 3.9: Branded long-acting human insulin analogs
Table 4.10: Frequency and level of dose of OADs
Table 4.11: US/European* OAD category market share (%), 2002-2003
Table 4.12: US/European* OAD Market Share by Company (%), 2002-2003
Table 4.13: Sales of leading sulfonylureas by country ($m), 2002-2003
Table 4.14: Branded sulfonylureas
Table 4.15: Sales of leading biguanides by country ($m), 2002-2003
Table 4.16: Branded biguanides
Table 4.17: Proportion of patients receiving monotherapy versus combination therapy treatment (%), 2003
Table 4.18: US/European* sales of sulfonylurea + biguanide single-pills ($m), 1999-2003
Table 4.19: Sales of leading TZDs by country ($m), 2002-2003
Table 4.20: Branded TZDs
Table 4.21: Sales of leading AGIs by country ($m), 2002-2003
Table 4.22: Branded AGIs
Table 4.23: Sales of leading PGRs by country (%), 2002-2003
Table 4.24: Branded PGRs
Table 5.25: US/European* diabetes market share by company (%), 2002-2003
Table 5.26: US Insulin Market Share by Company (%), 2002-2003
Table 5.27: US/European* sales of Eli Lilly’s marketed diabetes portfolio ($m), 2002-2003
Table 5.28: Projected sales of Eli Lilly’s diabetes R&D pipeline ($m), 2007 & 2010
Table 5.29: European* insulin market share by company (%), 2002-2003
Table 5.30: US/European* sales of Novo Nordisk’s marketed diabetes portfolio ($m), 2002-2003
Table 5.31: Projected sales of Novo Nordisk’s diabetes R&D pipeline ($m), 2007 & 2010
Table 5.32: US/European* sales of Sanofi-Aventis’ marketed diabetes portfolio ($m), 2002-2003
Table 5.33: Projected sales of Sanofi-Aventis’ diabetes R&D pipeline ($m), 2003 & 2010
Table 5.34: US/European* sales of Takeda’s marketed diabetes portfolio ($m), 2002-2003
Table 5.35: Projected sales of Takeda’s diabetes R&D pipeline ($m), 2007 & 2010
Table 5.36: US/European* sales of GSK’s marketed diabetes portfolio, 2002-2003
Table 5.37: GSK’s diabetes R&D pipeline, 2003
Table 5.38: US OAD Market Share by Company (%), 2002-2003
Table 5.39: US/European* sales of BMS’s diabetes portfolio, 2002-2003
Table 5.40: Projected sales of BMS’s diabetes R&D pipeline ($m), 2007 & 2010
Table 5.41: Projected sales of Merck KGaA’s diabetes R&D pipeline ($m), 2007 & 2010
Customers who bought this item also bought
The World Diabetes Market, 2007-2025: An analysis of Diabetes Drug and Insulin Market
Competitor Analysis: Insulin
Market Research of Diabetes and its Treatment Medicine-Insulin in China, 2008
Pipeline Insight: Insulin Antidiabetics - Return to Injections - Alternative Delivery Methods Fall by the Wayside
Diabetes, Metabolic Syndrome and Cardiovascular Disease
Stakeholder Insight: Diabetes
Insulin Delivery Devices Market Analysis and Future Forecast
Pipeline Insight: Non-Insulin Antidiabetics - Type 2 Diabetes Unlikely To Develop Into a Switch Market
Insulin Delivery Systems Market Analysis (2007-2010)
Insulin Delivery Devices Pipeline Technology and Market Forecasts to 2015
The Diabetes Market Outlook to 2011
Pipeline Insight: Non-Insulin Antidiabetics – Incretin Mimetics – Leaders in a Diverse Pipeline
|
|
|
|
